Sakar Healthcare signs 40th deal with Zydus Lifesciences for oncology in GCC, emerging markets.
Company filed 23 MAs in EU, gained 5 approvals, developed 21 APIs, and focuses on integration.
Sakar Healthcare projects FY27 as a key year with stronger exports driving growth.
Rising oncology volumes are expected to further support Sakar Healthcare's growth.
Livesquawk •
Sakar Healthcare Q4 EBITDA rises to ₹262M, up from ₹157M YoY.
EBITDA margin improves to 36.9% from 31.3% YoY.